Skip to main content
logo
BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
0.8024
-0.0426 (-5.04%)
At close: Jul 29, 2026, 4:00 PM EDT
0.8101
+0.0077 (0.96%)
After-hours: Jul 29, 2026, 7:14 PM EDT

BioXcel Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.220.642.271.380.38-
Revenue Growth
--71.67%64.20%268.00%--
Gross Profit
-0.220.480.120.120.36-
Operating Income
-50.59-50.46-67.25-171.78-159.65-106.94
Net Income
-75.33-69.9-59.6-179.05-165.76-106.93
Earnings Per Share
-4.52-5.73-23.51-98.33-94.72-64.80
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
17.1828.7629.8565.22193.73232.97
Total Debt
100.29109.59102.57101.0493.841.11
Net Cash (Debt)
-83.11-80.84-72.72-35.8299.89231.86
Net Cash Growth
-----56.92%9.51%
Net Cash Per Share
-4.93-6.62-28.69-19.6757.05140.67

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-57.38-57.62-72.03-155.01-135.34-82.15
Capital Expenditures
----0.02-0.14-0.45
Free Cash Flow
-57.38-57.62-72.03-155.03-135.48-82.6
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-98.62%74.45%5.43%8.70%94.67%-
Operating Margin
-23204.10%-7859.97%-2967.56%-12448.00%-42572.00%-
Pretax Margin
-34556.88%-10887.38%-2630.14%-12974.86%-44201.87%-
Profit Margin
-34556.90%-10887.40%-2630.14%-12974.90%-44201.90%-
FCF Margin
-26321.60%-8974.30%-3178.60%-11233.80%-36128.00%-

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
38.3755.658.1963.981612.26-